FierceBiotech Jan 30, 2026 Corcept submitted lead asset for approval despite FDA flagging risk of ‘significant review issues’
FierceBiotech Jan 30, 2026 Amgen jilts Kyowa, exiting $400M autoimmune pact after running vast pivotal program
FierceBiotech Jan 30, 2026 Chugai drops only AI-assisted antibody from pipeline but still holds high hopes for tech
FierceBiotech Jan 30, 2026 Moderna offloads late-stage rare disease drug to Recordati for $50M upfront
FierceBiotech Jan 29, 2026 Formation Bio’s China shopping spree continues with $500M biobucks autoimmune pact
FierceBiotech Jan 29, 2026 Roche diagnostics business nudges up 2% in '25 as China headwinds buffet Asia-Pacific sales
FierceBiotech Jan 29, 2026 Belgium biotech Agomab outlines up to $212M Nasdaq debut to fund immunology trials
FierceBiotech Jan 29, 2026 Sanofi keeps mum on future of disappointing Denali pact after scrapping final RIPK1 inhibitor
FierceBiotech Jan 29, 2026 AstraZeneca vows $15B China investment to boost cell therapy and radioconjugate capabilities
FierceBiotech Jan 29, 2026 Repertoire adds Lilly to range of Big Pharma partners in autoimmune deal worth up to $2.69B
FierceBiotech Jan 28, 2026 Reducing animal testing 'an evolution and not a revolution' for life sci R&D, Charles River's incoming CEO says
FierceBiotech Jan 28, 2026 New compound shrinks brain tumors in mice, sparking hope for a glioblastoma pill